Skip to Content Top

OVER $2.5 BILLION

OBTAINED FOR MESOTHELIOMA PATIENTS & FAMILIES
X-ray findings
|

A Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With Relapsed or Refractory Malignant Mesothelioma With BAP1 Loss of Function

Tazemetostat is an investigational drug that kills cancer cells by stopping a gene called EZH2 from working. EZH2 affects how two other genes, INI1 and SMARCA4 work in cells.

In early clinical development, tazemetostat has demonstrated clinical activity and a generally well-tolerated safety profile in both patients with hematological malignancies and genetically defined solid tumors.

Currently, tazemetostat is being used as a single-agent therapy in multiple clinical trials, including Phase 2 clinical trials in patients with mesothelioma.

Please click on this link to determine your eligibility and latest clinical trial locations.

Our Mission

  • Medical Empowerment

    Get the information you need to make informed decisions about your treatment.

  • Legal Empowerment

    Get the compensation you need to address the financial cost of your illness.

  • Going For The Gold

    Helping empower our clients with over $2.5 Billion in recoveries. We fight for our clients!

  • Giving Back To The Community

    Unprecedented Support for Mesothelioma Research. See how we can help!

Get Empowered

We put your medical and personal needs first and provide compassionate representation.
  • Please enter your first name.
  • Please enter your last name.
  • Please enter your phone number.
    This isn't a valid phone number.
  • Please enter your email address.
    This isn't a valid email address.
  • Please make a selection.
  • Please enter a message.
  • By submitting, you agree to receive text messages from Worthington & Caron, PC at the number provided, including those related to your inquiry, follow-ups, and review requests, via automated technology. Consent is not a condition of purchase. Msg & data rates may apply. Msg frequency may vary. Reply STOP to cancel or HELP for assistance. Acceptable Use Policy